459
449 460
450 461
451 462
452 463
453 464
454 465
455 466
456 467
457 468
458 469
459 470
460 471
461 472
462 473
463 474
464 475
465 476
466 477
467 478
468 479
469 480
470 481
471 483
Scrivener Publishing
100 Cummings Center, Suite 541J
Beverly, MA 01915-6106
Publishers at Scrivener
Martin Scrivener ([email protected])
Phillip Carmical ([email protected])
Nanopharmaceutical Advanced Delivery Systems
Edited by
Vivek Dave
Nikita Gupta
Srija Sur
This edition first published 2021 by John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA and Scrivener Publishing LLC, 100 Cummings Center, Suite 541J, Beverly, MA 01915, USA
© 2021 Scrivener Publishing LLC
For more information about Scrivener publications please visit www.scrivenerpublishing.com.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
Wiley Global Headquarters
111 River Street, Hoboken, NJ 07030, USA
For details of our global editorial offices, customer services, and more information about Wiley prod-ucts visit us at www. wiley.com.
Limit of Liability/Disclaimer of Warranty
While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchant-ability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read.
Library of Congress Cataloging-in-Publication Data
ISBN 978-1-119-71166-7
Cover image: Pixabay.Com
Cover design by Russell Richardson
Set in size of 11pt and Minion Pro by Manila Typesetting Company, Makati, Philippines
Printed in the USA
10 9 8 7 6 5 4 3 2 1
Preface
Our intent in writing Nanopharmaceutical Advanced Delivery Systems was to provide a systematic understanding of various novel drug delivery systems and their preparation, characterization and impressive range of applications. These novel drug delivery systems demand a wide range of detailed knowledge of various drug delivery systems and their composition. Moreover, it is important to understand the properties of the various constituents of a nanoformulation that determine the preparative methods of the delivery systems and broadly ensure their properties. With this in mind, this book covers a wide range of pharmaceutical topics required to appropriately perform and evaluate the biological and biopharmaceutical impact of nanopharmaceuticals in living systems.
Historically, there have been many conventional dosage forms available on the market for the treatment of various diseases that are administered in particular doses at particular frequency. The biggest disadvantage of these dosage forms is the increased chance of missing a dose of short half-life drugs because they need to be frequently administered. The need for novel drug delivery systems began with the realization that new, better and safer drugs with longer half-lives have a large therapeutic index. Since conventional pharmaceutical dosage forms are incapable of controlling the rate of drug delivery to the target site, there is also an unnecessary distribution of the drug in non-target sites of the body. This is the main reason why conventional dosage forms need to be given in higher therapeutic doses, which in turn is responsible for certain severe adverse effects
